LINC01315: A non-protein-coding RNA molecule with potential drug targets in the brain

Target Name: LINC01315

NCBI ID: G102723775

LINC01315

Other Name(s): Long intergenic non-protein coding RNA 1315, transcript variant 1 | Lnc-C22orf32-1 | long intergenic non-protein coding RNA 1315 | C22orf32-1 | lnc-C22orf32-1

LINC01315: A non-protein-coding RNA molecule with potential drug targets in the brain

LINC01315 is a non-protein coding RNA (ncRNA) molecule that has been identified using RNA sequencing (RNA-seq) experiments. It is a transcribed region of DNA that is located between the intron and the 5' end of exon 1315 in the human genome.

The LINC01315 RNA-seq experiment identified a highly expressed gene in the brain, as well as genes that are highly expressed in various tissues and organs, including the brain. The most highly expressed gene in the brain is known as GABA, which is a well-known neurotransmitter that plays a crucial role in the regulation of neural activity.

The LINC01315 RNA-seq experiment also identified a number of potential drug targets. For example, the gene is highly expressed in the brain, which suggests that it may be involved in the regulation of brain function and behavior. Additionally, the gene is highly expressed in various tissues and organs, which suggests that it may be involved in the regulation of cellular processes that are important for overall health.

In conclusion, the LINC01315 RNA-seq experiment provides evidence that this non-protein coding RNA molecule is involved in a number of important cellular processes. Further research is needed to determine the full extent of its involvement and to determine whether it can be targeted as a drug or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1315

The "LINC01315 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01315 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets